Compare Stocks

→ World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACOR Acorda Therapeutics		$11.13	$0.61 ▼ $24.20	$820K	1.4	119,299 shs	416,900 shs
BVXV BiondVax Pharmaceuticals		$1.36	$1.25 ▼ $11.80	$2.54M	2.37	127,289 shs	23,000 shs
ENTX Entera Bio	$2.00 -3.4%	$1.65	$0.52 ▼ $3.35	$57.60M	1.7	209,199 shs	117,197 shs
IDRA Idera Pharmaceuticals		$0.50	$0.22 ▼ $8.67	$450.52M	1.25	464,030 shs	21,870 shs

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACOR Acorda Therapeutics	0.00%	0.00%	-94.63%	-96.12%	-92.66%
BVXV BiondVax Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-26.49%
ENTX Entera Bio	-6.76%	-6.76%	+32.69%	+141.85%	+195.67%
IDRA Idera Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)

Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.

Click here to find out what to do.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACOR Acorda Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BVXV BiondVax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ENTX Entera Bio	1.6639 of 5 stars	3.5	3.0	0.0	0.0	3.3	0.0	0.0
IDRA Idera Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACOR Acorda Therapeutics	N/A	N/A	N/A	N/A
BVXV BiondVax Pharmaceuticals	N/A	N/A	N/A	N/A
ENTX Entera Bio	3.00	Buy	$10.00	400.00% Upside
IDRA Idera Pharmaceuticals	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest BVXV, ENTX, ACOR, and IDRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
4/2/2024	ENTX Entera Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACOR Acorda Therapeutics	$117.63M	0.00	N/A	0.02	($127.17) per share	0.00
BVXV BiondVax Pharmaceuticals	N/A	N/A	N/A	N/A	($3.81) per share	N/A
ENTX Entera Bio	$130K	443.08	N/A	N/A	$0.36 per share	5.56
IDRA Idera Pharmaceuticals	N/A	N/A	N/A	0.29	$0.56 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACOR Acorda Therapeutics	-$252.85M	-$203.83	N/A	N/A	N/A	-214.95%	-2,206.93%	-83.28%	5/9/2024 (Estimated)
BVXV BiondVax Pharmaceuticals	-$5.80M	-$2.55	N/A	N/A	N/A	N/A	-346.36%	-29.52%	N/A
ENTX Entera Bio	-$8.89M	-$0.31	N/A	N/A	N/A	N/A	-101.78%	-83.90%	5/3/2024 (Estimated)
IDRA Idera Pharmaceuticals	$98.09M	-$0.32	N/A	N/A	N/A	N/A	-68.74%	-34.26%	N/A

Latest BVXV, ENTX, ACOR, and IDRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/8/2024	Q4 2023	ENTX Entera Bio	-$0.08	-$0.07	+$0.01	-$0.07	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACOR Acorda Therapeutics	N/A	N/A	N/A	N/A	N/A
BVXV BiondVax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ENTX Entera Bio	N/A	N/A	N/A	N/A	N/A
IDRA Idera Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACOR Acorda Therapeutics	3.07	0.33	0.26
BVXV BiondVax Pharmaceuticals	N/A	4.12	4.12
ENTX Entera Bio	N/A	10.32	10.32
IDRA Idera Pharmaceuticals	N/A	1.56	1.56

Ownership

Institutional Ownership

Company	Institutional Ownership
ACOR Acorda Therapeutics	12.71%
BVXV BiondVax Pharmaceuticals	11.83%
ENTX Entera Bio	14.11%
IDRA Idera Pharmaceuticals	12.18%

Insider Ownership

Company	Insider Ownership
ACOR Acorda Therapeutics	2.60%
BVXV BiondVax Pharmaceuticals	6.03%
ENTX Entera Bio	8.90%
IDRA Idera Pharmaceuticals	5.05%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ACOR Acorda Therapeutics	111	1.24 million	1.21 million	No Data
BVXV BiondVax Pharmaceuticals	33	1.87 million	1.76 million	Not Optionable
ENTX Entera Bio	17	28.80 million	26.24 million	Optionable
IDRA Idera Pharmaceuticals	32	62.36 million	59.21 million	Optionable

BVXV, ENTX, ACOR, and IDRA Headlines

Source	Headline
	Ekso Bionics (NASDAQ: EKSO) fool.com - April 11 at 12:41 PM
	Kiniksa Pharmaceuticals forbes.com - November 15 at 3:23 PM
	Idra Pin Code indiatvnews.com - August 24 at 7:09 PM
	Nabriva Therapeutics AG (NBRVF) investing.com - August 9 at 2:08 AM
	Tesla's Switch to Giga Press Die Castings for Model 3 Eliminates 370 Parts designnews.com - May 21 at 8:54 AM
	Marginalia npr.org - April 26 at 9:17 PM
	A mysterious rift propels the story in ‘Take What You Need’ washingtonpost.com - March 17 at 5:57 PM
	Idera Pharmaceuticals, Inc.: Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook finanznachrichten.de - January 18 at 7:34 AM
	Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic ... bakersfield.com - January 17 at 11:33 AM
	Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook finance.yahoo.com - January 17 at 11:33 AM
	Why Bed Bath & Beyond Shares Are Trading Higher By 17%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session msn.com - January 10 at 7:29 PM
	Idera (IDRA) Stock Soars on GlaxoSmithKline Partnership thestreet.com - January 4 at 12:55 PM
	Idera Pharmaceuticals, Inc.: Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update finanznachrichten.de - November 18 at 3:52 PM
	Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update finance.yahoo.com - November 14 at 5:55 PM
	Idera Pharma Acquires Rare Disease Player, Names New CEO finance.yahoo.com - September 29 at 3:46 PM
	Idera Pharma Shares Rise Nearly 18% After Aceragen Acquisition marketwatch.com - September 28 at 6:34 PM
	Idera Pharmaceuticals Acquires Aceragen finance.yahoo.com - September 28 at 6:34 PM
	Idera Pharmaceuticals Stock (NASDAQ:IDRA), Dividends benzinga.com - September 27 at 10:32 PM
	Idera Pharmaceuticals Reports Second Quarter 2022 Financial Results finance.yahoo.com - August 9 at 9:26 PM
	Idera Pharmaceuticals Inc. [IDRA] Is Currently 16.02 above its 200 Period Moving Avg: What Does This Mean? dbtnews.com - May 18 at 5:18 PM
	Idera halts melanoma trial for cancer candidate after early positive results seekingalpha.com - May 17 at 6:10 PM
	Why Are Idera Pharmaceuticals Shares Soaring Today finance.yahoo.com - May 17 at 6:10 PM
	Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC finance.yahoo.com - May 17 at 8:18 AM
	Idera Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update finance.yahoo.com - May 5 at 6:17 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Acorda Therapeutics

NASDAQ:ACOR

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.

BiondVax Pharmaceuticals

NASDAQ:BVXV

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Entera Bio

NASDAQ:ENTX

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and hGh for the GH deficiency. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Idera Pharmaceuticals

NASDAQ:IDRA

Aceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial